Nurix Therapeutics Q3 2026 Earnings: Revenue Hits $673.1 Million as Roche Deal Drives Profit
Nurix Therapeutics reported Q3 2026 revenue of $673.1M, up 8,426.3% YoY, driven by a Roche licensing deal. Net income was $549.8M, reversing a prior-year loss. Shares fell 2% in after-hours trading. The company has $1.1B in liquidity and a cash runway into 2H 2029. Revenue beat estimates, but much came from one-time license fees.
How this was made
The 30-second read
Why it matters
The earnings release highlights a one‑time licensing cash infusion that boosts cash but also creates dependency on Roche, leading to mixed market reaction.
Market read
The report provides fresh earnings data for a mid‑cap biotech, with a notable licensing revenue spike that may affect valuation of similar partnership‑heavy firms.
What to watch
Roche cost‑sharing reduces R&D expense; the $27M milestone from Sanofi, Pfizer, Gilead may signal additional future collaborations.
Background
Nurix Therapeutics is a clinical‑stage biotech focused on targeted protein degradation, recently advancing its BTK degrader into Phase 3.
Ticker impact
Nurix Therapeutics reported Q3 2026 earnings with $673.1M revenue and $4.73 EPS, driven by a $700M Roche upfront payment, causing a 2% after‑hours share decline.
likely modest downside as market prices in the Roche licensing revenue and higher admin costs
The earnings beat was offset by heavy reliance on a single licensing deal and a 2% post‑release price drop, suggesting short‑term pressure.
Market effects
Biotech licensing revenue models may be re‑valued; peers with similar collaboration structures could see comparable volatility.
U.S. biotech sector sees slight pullback as investors digest the earnings.
Limited to companies with large pharma partnership revenue streams.
Counterpoint
The Roche upfront payment provides a cash runway to 2029, potentially supporting a longer‑term upside despite short‑term sell‑off.
Key entities
- companyNurix Therapeutics
NASDAQ‑listed biotech reporting Q3 2026 earnings.
- partnerRoche
Pharma partner providing $700M upfront licensing payment.
